Delivery Order SPE2DB22D7065-SPE2DB25FH3ET
- Not listed
- The Defense Logistics Agency awarded a $15,380.88 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This contract, awarded on July 18, 2025, with an ultimate completion date of July 21, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $3,804.40 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials. The contract is a firm fixed price delivery order issued on July 18, 2025, with an ultimate completion date of July 21, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. No set-aside designation was used for...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,545.48 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, awarded on July 18, 2025, with no set-aside designation. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a contract ceiling value of $1,703.81. This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) in 3 ml vials, with a ceiling value of $1,112.89. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 21, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting AmerisourceBergen's capability to compete in open...
- The Defense Logistics Agency awarded a $7,556.52 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials, with performance completion targeted for July 21, 2025. This delivery order represents a firm fixed-price, non-set-aside competitive award executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's...
- The Defense Logistics Agency awarded a $66,741.92 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) vials on July 18, 2025, with an ultimate completion date of July 21, 2025. This is a firm fixed-price, non-set-aside contract with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials, with a ceiling value of $3,578.75. This competitively awarded, firm fixed-price delivery order was issued on July 18, 2025, with an ultimate completion date of July 21, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The U.S. Defense Logistics Agency (DLA) awarded a $14,143.79 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml pharmaceuticals. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, valued at up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary contract vehicle for Amerisourcebergen...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, a diabetes medication. The contract has a firm fixed price of $3,137.08 and a completion date of April 21, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical,...
- SPE2DB22D7065Indefinite Delivery Contract
- SPE2DB22D7065-SPE2DB25FH3ETDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,503.69 for Ozempic 2 mg/dose (8 mg/3 ml) pharmaceutical product on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price delivery order was not designated as a set-aside contract and will be performed at the vendor's facility in Conshohocken, Pennsylvania. The contract represents a continuation of the pharmaceutical supply relationship between DLA and AmerisourceBergen Drug Corp, a major healthcare solutions provider and critical vendor for federal medical procurement. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The arrangement demonstrates DLA's structured approach to pharmaceutical procurement through prime vendor contracts, with Ozempic being one of numerous diabetes and specialty medications supplied to Defense Health Agency and other federal healthcare systems through this flexible contracting mechanism.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 7/18/25 |